OvaScience to reel in $35M; New clues for curing HIV in some patients;

 @FierceBiotech: Novartis grabs FDA's coveted 'breakthrough' status for lung cancer drug. More | Follow @FierceBiotech

@JohnCFierce: Tillman Gerngross (Adimab) has a new biotech startup.Avitide. A service company: More | Follow @JohnCFierce

@RyanMFierce: Merck hit with delay on FDA review of top drug prospect. Article | Follow @RyanMFierce

> Investigators find that rapid antiviral response to new cases of HIV infection could deliver "functional cures." Report

> A Senate bill could boost the FDA budget despite the impact of sequestration. Item

> Venture-funded biotech Lithera has mounted a 500-patient Phase IIb study for an injected treatment to reduce body fat. Article

> OvaScience, a biotech focused on women's reproductive medicine, plans to raise $35 million in a financing. More

Pharma News

@FiercePharma: Claris injectables unit seen as M&A target for Teva, Pfizer, now that Mylan has Agila Specialties. More | Follow @FiercePharma

@EricPFierce: FDA acts quickly to assess potential cancer risks of Type 2 diabetes drugs, Merck's Januvia, Bemis' Byetta. Story | Follow @EricPFierce

> Vivus hopes weight-loss app will fatten up Qsymia sales. More

> Pfizer's Read gets small raise in tough year. Article

> Generic drugmakers concerned over FDA turmoil. More

Medical Device News

 @FierceMedDev: Intuitive slides as doc group slams robotic surgery 'hype.' More | Follow @FierceMedDev

 @MarkHFierce: A brain Dx would measure tumor DNA to gauge how advanced breast cancer patients are responding to drugs. Article | Follow @MarkHFierce

 @DamianFierce: Illumina has to fork over $96 million in a patent suit over sequencing. Story | Follow @DamianFierce

> Sorin banks on up to 30% profit growth in 2013. More

> Study: Johns Hopkins brain stent saves patients from blindness. Article

And Finally… Researchers poked fresh holes in the case for a causal link between hormone replacement therapy and breast cancer. Article

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.